Sugi Predict

Sugi Predict / Compounds / SCHEMBL1806253

SCHEMBL1806253

SCHEMBL1806253

COCOc1c(Br)cccc1C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ SRC P12931 1/20 0.39
▸ BACE1 P56817 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ TLR2 O60603 1/20 0.38
▸ ERN1 O75460 1/20 0.38
▸ TLR1 Q15399 1/20 0.38
▸ TLR6 Q9Y2C9 1/20 0.38
▸ PIM1 P11309 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ TRIM24 O15164 1/20 0.37
▸ TRIM33 Q9UPN9 1/20 0.37
▸ LMNA P02545 3/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29940732 1.00 CA1 (0.45) CA1CA2SRCBACE1ALDH1A1
SCHEMBL1303053 0.86 CA1 (0.40) CA1CA2SRCBACE1ALDH1A1
SCHEMBL6048618 0.83 CA1 (0.47) CA1CA2SRCBACE1ALDH1A1
SCHEMBL10265246 0.83 LMNA (0.50) CA1CA2SRCALDH1A1SMN1; SMN2
SCHEMBL5807282 0.82 CA1 (0.39) CA1CA2SRCALDH1A1SMN1; SMN2
SCHEMBL5846257 0.82 PTPN1 (0.42) BACE1ALDH1A1SMN1; SMN2HPGDPTPN1
SCHEMBL2043979 0.81 PTPN1 (0.53) CA1CA2SRCBACE1ALDH1A1
SCHEMBL3214106 0.81 ALDH1A1 (0.47) CA1CA2SRCBACE1ALDH1A1
SCHEMBL1293351 0.80 CA1 (0.61) CA1CA2SRCALDH1A1TLR2
SCHEMBL9454738 0.80 CA1 (0.67) CA1CA2SRCBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729516-A1 SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2026-04-22 — — EP disclosed
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2026-01-08 — — US disclosed
WO-2024260319-A1 SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏恩华药业股份有限公司 2024-12-26 — — WO disclosed
EP-4163276-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2023-04-12 — — EP disclosed
CN-115557929-A Somatostatin modulators and uses thereof 克林提克斯医药股份有限公司 2023-01-03 — — CN disclosed
US-20220380337-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-12-01 — — US disclosed
CN-109715612-B Somatostatin modulators and uses thereof 克林提克斯医药股份有限公司 2022-09-16 — — CN disclosed
EP-3484865-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2022-09-14 — — EP disclosed
US-11414397-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2022-08-16 — — US disclosed
EP-4021504-A1 THERAPY Vestlandets Innovasjonsselskap AS (NO) 2022-07-06 — — EP disclosed
WO-2018013676-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2018-01-18 — — WO disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 — — US disclosed
US-9815811-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2017-11-14 — — US disclosed
US-20170273961-A1 NOVEL IMINONITRILE DERIVATIVES CURADEV PHARMA, PVT. LTD. (IN) 2017-09-28 — — US disclosed
EP-2571353-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2017-08-09 — — EP disclosed
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2016-02-18 — — US disclosed
US-8846951-B2 Modulators of 5-HT receptors and methods of use thereof ABBVIE INC. (US) 2014-09-30 — — US disclosed
EP-2571353-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF AbbVie Inc. (US) 2013-03-27 — — EP disclosed
WO-2011146089-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-11-24 — — WO disclosed
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414397-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 CA1 1050/4885CA2 704/4885SRC 3211/4885
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 CA1 1050/4885CA2 704/4885SRC 3211/4885
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C CA1 3888/4885CA2 2905/4885SRC 1866/4885
US-20170273961-A1 NOVEL IMINONITRILE DERIVATIVES UGT1A4, XDH, CYP4B1 CA1 2956/4885CA2 3115/4885SRC 4329/4885
US-20220380337-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 CA1 1050/4885CA2 704/4885SRC 3211/4885
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY IDO1, KYNU, IDO2 CA1 1280/4885CA2 1639/4885SRC 2410/4885
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR3, SSTR2 CA1 260/4885CA2 127/4885SRC 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.